Equity research · The long view

Investment research through a long-term owner's lens

The Zen Horizon Framework, dissecting the business quality, moats, and intrinsic value of AI, technology, and global equities — with a clear read on the margin of safety.

1140 reports15 topics1095 tickers

Latest Research

More research

37/100 65Buffett Hold Reliance: Q2's 5.3-Point Industry Beat Shrinks to 0.1 Point Without the Border Wall, and $387.59 Already Sits Inside the Base-Case Band Reliance is North America's largest metals-service-center network, buying metal from mills, carrying thousands of grades in inventory, processing it to customer specification and delivering small lots fast, so it earns processing and distribution spreads rather than steel prices. Q2 2026 tons rose 10.8% against 5.5% for the MSCI industry benchmark, but the Department of Homeland Security border-wall project supplied 5.2 of those points, leaving underlying growth of about 5.6% and an industry beat of one-tenth of a point. Rating Hold: at $387.59 the shares sit inside the $350 to $420 base band and 19% to 27% above the conservative value, with the ideal buy zone at $230 to $240 and no margin of safety today. Reliance, Inc.RS · USIndustrial DistributionAug 30, 2026 43/100 78Buffett Hold NEXT plc: 23.9% International Growth, a £16.9 Million Platform, and 19.2 Times Earnings NEXT plc is a UK omnichannel fashion and home retailer whose profit now runs through four engines: UK online, which earned £524 million of statutory pre-tax profit in the year to 2026-01-31 against £226 million from stores; international online, up 23.9% in the 26 weeks to 2026-08-01; NEXT Finance, contributing £195 million; and a portfolio of distressed brands bought cheaply. Management raised guidance for the year to January 2027 to £1.243 billion, though £10 million of the £25 million upgrade came from investments rather than retail, and Total Platform services earned only £16.9 million. Rating Hold: the international re-rating is real, but £155.75 is 19.2 times guided earnings and a 3.8% owner-cash yield against a 5.15% gilt, leaving no margin of safety above the £100–105 ideal buy range. NEXT plcNXT · LSERetailAug 30, 2026 44/100 Hold Metso: A 56% Aftermarket Mix, an 18.0% Minerals Margin, and 30 Times Earnings Metso is a Finnish supplier of mineral-processing and aggregates equipment whose economics rest on the aftermarket: wear parts, mill linings, screening media and service were 56% of first-half 2026 group sales and 65% of Minerals sales. First-half orders rose 12% to EUR 3.017 billion and the backlog reached EUR 3.662 billion, up 13%, while the Minerals adjusted EBITA margin hit 18.0% against 16.4% for the group; operating cash flow nonetheless fell to EUR 131 million from EUR 283 million as working capital absorbed EUR 186 million. Rating Hold: the installed-base quality is real, but at EUR 18.19 the shares carry roughly 30 times trailing earnings and a 3.0% free-cash-flow yield, leaving no margin of safety until the price approaches the EUR 10.0 to 11.2 ideal buy range. Metso OyjMETSO · HEConstruction MachineryAug 30, 2026 41/100 45Buffett Hold GoerTek: Stand-Alone Q2 Grew 0.67%, FY2025's Profit Jump Was Largely an Accounting Gain, and CNY 23.51 Already Pays the Base Case GoerTek is a Chinese acoustic and sensing component supplier that also assembles TWS earbuds and VR/XR smart hardware at very large scale, with roughly four-fifths of revenue sitting in low-margin assembly and the best economics concentrated in precision components. Stand-alone Q2 2026 revenue grew only 0.67% once the first quarter is subtracted from the half year, and FY2025's 47.85% profit jump rested on a CNY 2.14 billion one-off gain from deconsolidating GoerTek Optical, leaving adjusted profit down 38.17%. Rating Hold: at CNY 23.51 the shares already sit on the CNY 24.8 base-case value and 36% above the CNY 17.3 conservative estimate, with no margin of safety ahead of the CNY 13.0 to 13.8 ideal buy range. GoerTek Inc.002241 · ShenzhenElectronics Manufacturing ServicesAug 30, 2026

Insights

All insights

The Global Defense Supply Chain

54 tickers

From specialty materials to prime platforms: a complete supply-chain map for the rearmament cycle

Cancer · Rare Disease · Hard-to-Treat Frontiers

108 tickers

Targeted / immuno / cell / gene / nucleic-acid / radiopharmaceuticals: a map of the frontier therapies attacking high-unmet-need diseases, with the global and Chinese players building them

Niche Champions Across Every Industry

90 tickers

Companies that own a narrow track, ranking first or top-three globally and holding real pricing power: niche champions in critical links of the chain. The framing follows Hermann Simon's "hidden champions," but relaxes his size and obscurity thresholds (no cap on size, no requirement to stay low-profile). What counts is how narrow the track is and how deeply entrenched the position, laid out across eight functional domains.

Don't see a stock you follow? Request custom research